Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy
ConditionSCLC,Extensive Stage
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorTang-Du Hospital
About this trial
This prospective clinical study aims to evaluate and observe the efficacy and safety of adebrelimab combined with etoposide capsules in maintenance therapy for extensive-stage small cell lung cancer using a single-arm trial design.
The study is planned to be conducted in Shaanxi Province, China, with an initial target enrollment of 32 patients. The study commenced in August 2025, and recruitment is expected to conclude around December 2026, with the trial anticipated to end by December 2027. Assuming no occurrences such as withdrawal of informed consent by subjects, intolerable adverse drug reactions, or investigator-assessed unsuitability for further participation, each participant's estimated duration of study treatment will continue until radiographically confirmed tumor progression.
Eligibility criteria
Qualifiers
Voluntary participation with signed informed consent and good compliance for follow-up.
Age between 18 and 75 years old.
Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) according to the AJCC 8th edition or VALG phase II staging criteria.
ECOG performance status score: 0 to 2.
Disqualifiers
Limited-stage small cell lung cancer (SCLC);
Histologically or cytologically confirmed mixed histology SCLC;
Prior treatment with anti-angiogenic agents;
Conditions that may affect oral drug intake, such as inability to swallow, chronic diarrhea, or intestinal obstruction;
Trial design
Treatments tested in this trial
- Adebrelimab combined with Etoposide Capsules
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov